Qualisys receives an honorary mention in the quality category in Affärsvärlden’s 2025 IPO Guide, standing out by having no flags in the review of Swedish initial public offerings.
Among small-cap companies, an average of two warning flags per company were identified. These flags indicate potential risks or areas that investors should pay attention to, such as financial stability, management experience, or other factors that could affect the company’s future development.
“It is very gratifying to see the strong interest in our company, and we are proud to have received Affärsvärlden’s recognition of the focused and IPO guide honorable mention for quality. The award is a clear long-term work our team has put into the company’s growth journey. We also want to extend a warm thanks to the Board and our partners – Avanza, MAQS, and SKGM – whose commitment has been crucial for the execution of the IPO. Now we look forward to continuing our development together with both new and existing shareholders,” says Ingemar Pettersson, CEO of Qualisys.
Qualisys develops and delivers advanced motion capture systems that enable precise real-time motion analysis. The solutions are used by customers in life sciences, engineering, and entertainment to drive research, product development, and innovation forward.
“Our commitment to precision and reliability is a guiding principle throughout our business and a key factor in getting us to where we are today. From technology and delivery to customer relationships, it permeates everything we do. With our highly accurate solutions, we help our customers make informed decisions and achieve new breakthroughs,” says Ingemar Pettersson.
Qualisys is a leading provider of motion capture technology and has a long history of supplying research, engineering, entertainment, and sports facilities with high-end camera systems and expertise in capturing and analyzing movements. Qualisys offers a wide range of products and services and has offices in Gothenburg, Chicago, Singapore, Shanghai and Delhi. Qualisys is certified according to ISO 9001:2015, our clinical products are compliant with Medical Device Directive 93/42/EEC and have FDA clearance (K171547).